SEGURIDAD Y TOLERABILIDAD DE WVE-120101 EN PACIENTES CON ENFERMEDAD DE HUNTINGTON
Wave Life Sciences compartió que sus dos ASOs en ensayos de fase 1/2 en pacientes con EH no lograron reducir la huntingtina mutante.
PRECISION-HD1 está probando un nuevo fármaco que reduce selectivamente la proteína mutante de la enfermedad de Huntington, mientras que deja la proteína huntingtina normal relativamente intacta. Para poder identificar el gen con la Huntingtina mutante, utilizan un método único e identifican los llamados SNP (polimorfismos de nucleótido único). Wave ha identificado dos SNPs diferentes que ayudan a localizar la Huntingtina mutante y, por lo tanto, hay dos estudios (Presicion HD 1 y Presicion HD 2) con el mismo tratamiento, en los que la única diferencia es el SNP al que se apunta. El objetivo principal es comprender si el fármaco es seguro en un pequeño número de voluntarios, antes de probarlo en una población mayor y recoger pruebas de que el fármaco puede funcionar. Un total de 60 participantes reciben un placebo o diferentes dosis del fármaco activo cada 4 semanas. Tanto el fármaco activo como el placebo se administran mediante inyecciones en la columna vertebral.
Fecha estimada de finalización del estudio: Diciembre de 2020
25 años a 65 años (adulto, adulto mayor)
Todos
No
TRIAL SITE:
University Hospital of Aarhus
Address: Aarhus, Denmark, 8000
CONTACT
Anette T Moller
Tel: Not available
TRIAL SITE:
Rigshospitalet
Address: Copenhagen, Denmark, DK2100
CONTACT
Lena Hjermind
Tel: Not available
TRIAL SITE:
Odense University Hospital and University of Southern Denmark
Address: Odense, Denmark, 5000
TRIAL SITE:
Hospital Henri Mondor
Address: Créteil, France, 94010
CONTACT
Katia Youssov
Tel: Not available
TRIAL SITE:
Institut du Cerveau et de la Moelle Epinière
Address: Paris, France, 75646
CONTACT
Alexandra Dürr
Tel: Not available
TRIAL SITE:
George-Huntington- Institut GmbH
Address: Münster, Germany, 48149.
CONTACT
Ralf Reilmann
Tel: 49 (0)251 788 788 0 (George-Huntington- Institut)
TRIAL SITE:
Szpital Sw. Wojciecha
Address: Gdańsk, Poland, 80-462
CONTACT
Jaroslaw Slawek
Tel: Not available
TRIAL SITE:
Instytut Psychiatrii i Neurologii
Address: Warsaw, Poland, 02-957
CONTACT
Grzegorz Witkowski
Tel: Not available
TRIAL SITE:
Royal Devon and Exeter Hospital NHS Trust
Address: Exeter, Devon, United Kingdom, EX2 5DW
CONTACT
Timothy P Harrower
Tel: Not available
TRIAL SITE:
Queen Elizabeth University Hospital – PPDS
Address: Glasgow, Glasgow City, United Kingdom, G12 0XH
CONTACT
Stuart Richie
Tel: Not available
a single-letter spelling difference in a gene. SNPs, pronounced ‘snips’, are common and most don’t change the function of the gene.
You do not know if you carry the genetic mutation for HD gene
A standardized rating scale for function in HD, used to assess capacity to work, handle finances, perform domestic chores and self-care tasks.
Scores range from 0 to 13, with higher scores indicating better functional capacity.
means that neither the participant nor the clinical trial doctor can choose or know the group the participant is in until the trial is over. This approach helps to prevent bias.
A trial in which the patient and doctor know what drug is being used. Open label trials are susceptible to bias through placebo effects.
a technique that aims to treat or prevent diseases by modifying a person’s genes. It involves introducing, removing, or changing genetic material (DNA or RNA) within a patient’s cells.
A standardized neurological examination that aims to provide a uniform assessment of the clinical features of HD
The stretch of DNA at the beginning of the HD gene, which contains the sequence CAG repeated many times, and is abnormally long in people who will develop HD
the opposite of ‘mutant’. Wild-type huntingtin, for example, is the ‘normal’, ‘healthy’ protein
How well a person can handle a treatment without having serious or uncomfortable side effects.
Part of the brain that coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward system.
A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.
a radioactive substance that binds to a specific target in the body, allowing visualization of that target’s distribution and activity
Protein builds, maintains, and replaces the tissues in your body. The building blocks of life.
Prior to onset or diagnosis of movement symptoms.
A placebo is a dummy medicine containing no active ingredients. The placebo effect is a psychological effect that causes people to feel better even if they’re taking a pill that doesn’t work.
The movement of drugs through the body
The body’s biological response to drugs
Positron emission tomography which produces detailed 3-dimensional images of the inside of the body.
Brain cells that store and transmit information
Magentic resonance imaging: A technique using powerful magnetic fields to produce detailed images and visualizes the structure of organs, tissues, and bones
Mutant huntingtin protein. The protein produced by the faulty HD gene.
after HD diagnosis, or when symptoms are already showing
A study where each participant is looked at several times over a time period – unlike a cross-sectional study, where each participant is looked at only once
one abbreviation for the gene that causes Huntington’s disease. The same gene is also called HD and IT-15
functional MRI:As with MRI, a technique using powerful magnetic fields but focusing on brain function by measuring and mapping changes in blood flow, revealing which areas of the brain are active during specific tasks or cognitive processes
A clear fluid produced by the brain, which surrounds and supports the brain and spinal cord.
A measure of whether a treatment works or not
A type of gene silencing treatment in which specially designed DNA molecules are used to switch off a gene
a test of any kind – including blood tests, thinking tests and brain scans – that can measure or predict the progression of a disease like HD. Biomarkers may make clinical trials of new drugs quicker and more reliable
Brain-derived neurotrophic factor: a growth factor that may be able to protect neurons in HD.
one of the two copies of a gene
Liquid component of the blood.
The basic unit of heredity passed from parent to child. Genes are made up of sequences of DNA and are arranged, one after another, at specific locations on chromosomes in the nucleus of cells.
Each phase has a specific goal and involves a different number of participants. Generally, there are 4 phases (I-IV), with Phase I focusing on safety and dosage, Phase II on efficacy and side effects, Phase III on comparing the new treatment with standard treatments, and Phase IV on long-term safety monitoring.
